Updated proceeds from Dendreon Corp...

Updated proceeds from Dendreon Corporation's (Seattle, WA) ongoing Phase 1 trial of APC8024, an immunotherapy for breast, colon and ovarian cancer, indicate the issue is showing continued clinical benefit and targeted T-cell immune rejoinders in subjects with advanced, metastatic, HER-2 positive breast cancer. In addition, conclusions demonstrated a durable immune answer could be boosted by retreatment with the work Updated results were presented forward 16 subjects with advanced, metastatic, HER-2 positive breast cancer (3+ according to immunohistochemistry or positive according to FISH) whose disease ...